Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (8414)	7/20/1998 1:06:00 AM
From: scaram(o)uche	Respond to of 9262

Rainier, Carol, John, other biofreaks...... BTRN , StoT , 3.250 , -12 , 49 , 07/15/1998 Last week, Ray already said that he's not certain about this issue. I don't know when the timing will be best, but.... I sincerely believe that this issue stands a damn good shot at 10X or better within two years. Best known for procedures to eliminate the need for toxic drugs that suppress the immune response to transplanted human tissues (no partner, just entered phase I human testing) and to facilitate pig -----> human organ transfer (partnered with Novartis), they have a competitive project with MedImmune that addresses biggie markets. I consider the project with MedImmune, a humanized monoclonal, to be a competitive effort addressing autoimmune diseases and a variety of unwanted immune attacks relating to transplantation. Near-term downside is minimal, as they may also make Ray's book value scan. :-) There appears to be a seller that is hell bent to get out, so I'm not suggesting that there is any hurry. However, I highly recommend studying this one, and considering the wisdom of a longer-term bet. Cheers! Rick